Clinical trials
General Population (no Specific Condition or Disease) clinical trials
Below are recruiting general population (no specific condition or disease) clinical trials, each written for real people, not researchers. We’re tracking 10,808 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89 - NCT07226193Recruiting
Can a pulse test detect PAD?
This study is testing a simple pulse check to see if it can detect peripheral artery disease (PAD), a condition that narrows leg arteries. People with or without PAD can join to help see how well the test works.
Omaha, NebraskaAges 19 years+ - NCT07226219RecruitingPhase 1
Methylphenidate for Attention in Sickle Cell Disease
This trial tests if a medication called methylphenidate can help children with sickle cell disease who have trouble with attention, focus, or executive function. It aims to see if it can improve daily life and school performance.
Memphis, TennesseeAges 8–17 - NCT07229144RecruitingPhase 1
Study of OM336 for people with active autoimmune diseases
This trial tests a new treatment called OM336 for people with active autoimmune diseases that have not improved after at least two other treatments. The goal is to see if OM336 can help control the disease.
Hamilton, Waikato RegionAges 18–75 - NCT07229651RecruitingPhase 2/Phase 3
Metformin for Parkinson's disease
This trial tests if metformin, a diabetes drug, can help people with Parkinson's disease. It may improve symptoms or slow progression.
TantaAges 50–70 - NCT07229664RecruitingPhase 2/Phase 3
Vinpocetine for Parkinson's disease
This trial tests if adding vinpocetine to standard levodopa treatment can help Parkinson's disease patients. It aims to see if this combination improves symptoms.
TantaAges 50–70 - NCT07230847Recruiting
Healing of drug-coated vs. standard stents in high-bleeding-risk patients
This trial compares two types of stents (a drug-coated stent and a standard drug-eluting stent) in people with acute coronary syndrome who also have a high risk of bleeding. It uses a special camera to look at how the artery heals one month after the stent is placed.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07231679RecruitingPhase 1/Phase 2
Testing IGT-303 for kidney disease from diabetes
This study tests a new drug called IGT-303 for people with chronic kidney disease caused by type 2 diabetes. It aims to see if the drug is safe and can help protect kidney function.
Herston, BrisbaneAges 18–75 - NCT07232537Recruiting
Study of finerenone in kidney disease with diabetes
This study is for people in South Korea who have chronic kidney disease and type 2 diabetes and are already taking or about to start the medicine finerenone (Kerendia). The goal is to see how well finerenone works in everyday medical care, outside of a strict research setting.
Multiple LocationsAges 18 years+ - NCT07235059RecruitingPhase 1
Testing OJR520 in healthy people and those with chronic kidney disease
This study tests a new drug called OJR520 to see if it's safe and how the body processes it. It first tests healthy volunteers and then people with chronic kidney disease to understand the drug's effects.
Miami, FloridaAges 18–65 - NCT07235709Recruiting
Study of agalsidase alfa for heart inflammation in Fabry disease
This trial tests whether agalsidase alfa can reduce heart inflammation in people with Fabry disease who have heart problems. You may qualify if you have not had this treatment in the past year.
SeoulAges 15–75 - NCT07238920Recruiting
Brain training for heart health in people with coronary artery disease and anxiety
This trial tests a brain-training technique called neurofeedback, which uses a video game controlled by your brain activity to help your heart and nervous system work better. It is for people with both coronary artery disease and anxiety who want to improve their heart health and manage anxiety without medication.
Shenyang, LiaoningAges 18 years+ - NCT07239570RecruitingPhase 4
Using biomarkers to personalize kidney disease treatment
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
HerlevAges 18–75 - NCT07240896RecruitingEarly Phase 1
Testing a new mRNA therapy for Wilson disease
This trial tests an experimental mRNA treatment (DSL101) for adults with Wilson disease. It's for people whose condition is stable on current therapy and who have certain genetic markers. The goal is to see if the new treatment can help the body process copper better and reduce the need for standard medicines.
Hefei, AnhuiAges 18 years+ - NCT07241195Recruiting
Fatty Liver Study in Older Adults
This study follows older adults with fatty liver disease to understand how their metabolism changes over time and how it affects their overall health. It helps researchers learn more about the condition and its impact on the body outside the liver.
Hangzhou, ZhejiangAges 65–100 - NCT07244484Recruiting
Brain Training for Heart Health in Coronary Artery Disease with Anxiety
This trial tests a brain training technique (neurofeedback) to help people with coronary artery disease and anxiety. It aims to improve heart rate control by targeting a specific brain area.
Shenyang, LiaoningAges 18 years+ - NCT07244640Recruiting
Detecting Parkinson's through eye scans
This study uses a special eye camera to see if early signs of Parkinson's and similar movement disorders can be spotted in the retina. It may help doctors diagnose these conditions sooner and more easily.
Hangzhou, ZhejiangAges 40–80 - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07246278RecruitingPhase 1/Phase 2
Celecoxib for Parkinson's: A new way to treat symptoms
This trial tests if adding celecoxib, an anti-inflammatory drug, to standard Parkinson's treatment can help improve symptoms. If you have Parkinson's disease and are at least 18, this study might be an option for you.
TantaAges 50–80 - NCT07247188RecruitingPhase 3
Pneumococcal vaccine study for children with sickle cell disease
This trial tests a single dose of a new pneumococcal vaccine (21-valent) in children and teens with sickle cell disease. It aims to see if the vaccine can help protect against serious infections caused by pneumococcus bacteria, which are especially dangerous for people with SCD.
Atlanta, GeorgiaAges 2–17 - NCT07680725Recruiting
Bottle breathing exercise for Parkinson's: muscle strength and balance
This trial tests if a simple breathing exercise using a bottle can strengthen the muscles you use to breathe and improve your balance. It may help people with Parkinson's who can walk on their own.
Istanbul, MaltepeAges 18–75 - NCT07680335Recruiting
Blood test to help diagnose Alzheimer's earlier
This study is testing whether a simple blood test can help doctors diagnose Alzheimer's disease earlier and more accurately. It's for people who are having memory or thinking problems and are visiting a memory clinic.
Amsterdam, North HollandAges 55 years+ - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120 - NCT03990428Recruiting
Support program study for caregivers of rare blood cancers
This study looks at what support caregivers of people with Erdheim-Chester disease and related rare conditions need. It may help improve caregiver support so families cope better while the patient is being treated.
New York, New YorkAges 18 years+
Hear when a new General Population (no Specific Condition or Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for general population (no specific condition or disease)?
- Yes. Clin2 currently lists 10,808 recruiting general population (no specific condition or disease) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a general population (no specific condition or disease) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a general population (no specific condition or disease) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.